Updating results

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

Proposed [GID-TA10429] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing cluster headache [ID1212]

Proposed [GID-TA10425] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: TBC

Technology appraisal guidance Proposed

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Diverticular disease

Proposed [GID-QS10086] Expected publication date: TBC

Quality standard Proposed

Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Technology appraisal guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing migraine [ID1372]

Proposed [GID-TA10454] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Proposed [GID-TA10457] Expected publication date: TBC

Technology appraisal guidance Proposed

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Proposed [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Acne

Proposed [GID-QS10036] Expected publication date: TBC

Quality standard Proposed

Adrenal dysfunction

Proposed [GID-QS10038] Expected publication date: TBC

Quality standard Proposed

Tinnitus

Proposed [GID-QS10091] Expected publication date: TBC

Quality standard Proposed

Primary and secondary brain cancers

Proposed [GID-QS10092] Expected publication date: TBC

Quality standard Proposed

Pain management (young people and adults)

Proposed [GID-QS10093] Expected publication date: TBC

Quality standard Proposed

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery (ID1105)

Proposed [GID-TA10348] Expected publication date: TBC

Technology appraisal guidance Proposed

Ozanimod for treating relapsing multiple sclerosis [ID1294]

Proposed [GID-TA10299] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Technology appraisal guidance Proposed

Pancreatitis (including acute pancreatitis)

Proposed [GID-QS10085] Expected publication date: TBC

Quality standard Proposed

Thyroid disease

Proposed [GID-QS10088] Expected publication date: TBC

Quality standard Proposed

Primary hyperparathyroidism

Proposed [GID-QS10089] Expected publication date: TBC

Quality standard Proposed

Perioperative care

Proposed [GID-QS10094] Expected publication date: TBC

Quality standard Proposed

Sleep disordered breathing

Proposed [GID-QS10096] Expected publication date: TBC

Quality standard Proposed

Shared decision-making: practical guidance for health and social care professionals

Proposed [GID-QS10097] Expected publication date: TBC

Quality standard Proposed

Heart valve disease in adults

Proposed [GID-QS10101] Expected publication date: TBC

Quality standard Proposed

Infant, children and young people's experience of health care

Proposed [GID-QS10102] Expected publication date: TBC

Quality standard Proposed

Managing symptoms with an uncertain cause

Proposed [GID-QS10103] Expected publication date: TBC

Quality standard Proposed

Readmission to ICU within 48hrs

Proposed [GID-QS10105] Expected publication date: TBC

Quality standard Proposed

Prevention of dementia

Proposed [GID-QS10109] Expected publication date: TBC

Quality standard Proposed

Road safety

Proposed [GID-QS10111] Expected publication date: TBC

Quality standard Proposed

Spatial planning

Proposed [GID-QS10112] Expected publication date: TBC

Quality standard Proposed

Mental well-being: life course, settings and subgroups

Proposed [GID-QS10118] Expected publication date: TBC

Quality standard Proposed

Heat wave planning

Proposed [GID-QS10116] Expected publication date: TBC

Quality standard Proposed

Natural environments

Proposed [GID-QS10119] Expected publication date: TBC

Quality standard Proposed

Non-antibiotic clinical management of infectious diseases

Proposed [GID-QS10120] Expected publication date: TBC

Quality standard Proposed

Programme management: effective ways to run public health programmes to generate a change in behaviour

Proposed [GID-QS10122] Expected publication date: TBC

Quality standard Proposed

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

Proposed [GID-TA10385] Expected publication date: TBC

Technology appraisal guidance Proposed

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Proposed [GID-TA10390] Expected publication date: TBC

Technology appraisal guidance Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed